{"title":"The Feasibility and Applicability of Pediatric Inpatient Beta Lactam De-Labeling: From Bedside Challenge to Long-Term Follow Up.","authors":"Michal Paret, Rinat Komargodski, Bella London, Hadas Paz, Naama Epstein Rigbi","doi":"10.3947/ic.2025.0077","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Beta-lactam allergy (BLA) labels are common in pediatric patients but are often inaccurate, leading to unnecessary use of second-line antibiotics. While direct oral challenge tests (OCTs) are effective for de-labeling, their implementation in inpatient pediatric settings remains underexplored. This study aimed to evaluate the feasibility and barriers of an inpatient pediatric BLA de-labeling program, from bedside OCT to long-term follow-up and integration into electronic medical records (EMRs).</p><p><strong>Materials and methods: </strong>We conducted a prospective interventional study in the pediatric ward between 2019 and 2024. Hospitalized children with a documented BLA were screened and eligible patients underwent a 2-step graded OCT. In-house pediatricians completed surveys to assess beliefs and barriers regarding inpatient OCT implementation. Long term follow-up included caregiver surveys and review of hospital and Health Maintenance Organization (HMO) EMRs to evaluate de-labeling documentation and subsequent beta-lactam use.</p><p><strong>Results: </strong>Of 192 eligible BLA-labeled patients, 32 (16.6%) were recruited, 93.8% carrying an amoxicillin allergy label and the vast majority without other drug allergy labels. All patients had a history of a mild reaction, 100% presented with a benign rash. 30/32 (93.4%) had a negative OCT. Pediatricians faced challenges such as workload pressures, staff shortages and overestimation of severe reaction risks, all serving as barriers for patient recruitment. At follow-up (median 37 months), 35.7% of caregivers reported de-labeling, while EMRs documented higher rates (HMO: 80%; hospital: 70%). Despite successful OCTs, discrepancies between caregiver understanding, physician attitudes, and EMR documentation persisted.</p><p><strong>Conclusion: </strong>While direct OCTs are proved to be effective in de-labeling BLA, significant challenges persist in implementing inpatient de-labeling and ensuring their long-term success. These include low recruitment rates, pediatricians' misconceptions and incomplete integration into EMRs. Addressing these barriers requires targeted education, improved communication, and streamlined processes to improve de-labeling outcomes and support antibiotic stewardship.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"29-38"},"PeriodicalIF":2.9000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13053898/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3947/ic.2025.0077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Beta-lactam allergy (BLA) labels are common in pediatric patients but are often inaccurate, leading to unnecessary use of second-line antibiotics. While direct oral challenge tests (OCTs) are effective for de-labeling, their implementation in inpatient pediatric settings remains underexplored. This study aimed to evaluate the feasibility and barriers of an inpatient pediatric BLA de-labeling program, from bedside OCT to long-term follow-up and integration into electronic medical records (EMRs).
Materials and methods: We conducted a prospective interventional study in the pediatric ward between 2019 and 2024. Hospitalized children with a documented BLA were screened and eligible patients underwent a 2-step graded OCT. In-house pediatricians completed surveys to assess beliefs and barriers regarding inpatient OCT implementation. Long term follow-up included caregiver surveys and review of hospital and Health Maintenance Organization (HMO) EMRs to evaluate de-labeling documentation and subsequent beta-lactam use.
Results: Of 192 eligible BLA-labeled patients, 32 (16.6%) were recruited, 93.8% carrying an amoxicillin allergy label and the vast majority without other drug allergy labels. All patients had a history of a mild reaction, 100% presented with a benign rash. 30/32 (93.4%) had a negative OCT. Pediatricians faced challenges such as workload pressures, staff shortages and overestimation of severe reaction risks, all serving as barriers for patient recruitment. At follow-up (median 37 months), 35.7% of caregivers reported de-labeling, while EMRs documented higher rates (HMO: 80%; hospital: 70%). Despite successful OCTs, discrepancies between caregiver understanding, physician attitudes, and EMR documentation persisted.
Conclusion: While direct OCTs are proved to be effective in de-labeling BLA, significant challenges persist in implementing inpatient de-labeling and ensuring their long-term success. These include low recruitment rates, pediatricians' misconceptions and incomplete integration into EMRs. Addressing these barriers requires targeted education, improved communication, and streamlined processes to improve de-labeling outcomes and support antibiotic stewardship.